Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation‐Positive Solid Tumors

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|53|9|955-961

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.53, Iss.9, 2013-09, pp. : 955-961

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation‐positive metastatic melanoma, including recognition and management of rare presentations

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 1024-1031

John Wiley & Sons Inc

Access to resources Recommend Favorite

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-04 ,pp. : 241-245

Karger

Access to resources Recommend Favorite

Assessment of the drug interaction potential and single‐ and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 4, 2015-04 ,pp. : 392-400

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genetic study of the BRAF gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients

By  

JOURNAL OF ORAL PATHOLOGY & MEDICINE, Vol. 47, Iss. 1, 2018-01 ,pp. : 86-90

John Wiley & Sons Inc

Access to resources Recommend Favorite

BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 3, 2015-03 ,pp. : 359-364

John Wiley & Sons Inc

Access to resources Recommend Favorite